BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BioCentury | Mar 21, 2020

Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia. SR One led...
BC Innovations | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BC Innovations | Dec 19, 2018
Distillery Therapeutics


INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the BRD4-FOXO3-CDK6 axis could help treat luminal breast cancer resistant to AKT inhibitors. In patients who had been treated for hormone receptor-positive luminal...
BC Innovations | Dec 11, 2018
Distillery Therapeutics


INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Oct 3, 2018
Distillery Therapeutics


INDICATION: Lung cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting the METTL3-EIF3H interaction could help treat lung and other cancers. In tumor samples from patients with lung adenocarcinoma or seven other cancers,...
BC Innovations | Sep 10, 2018
Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML) Cell culture studies identified a pteridinylbenzamide-based dual PLK1/BRD4 inhibitor that could help treat AML. Chemical synthesis and screening of analogs of a pteridinylbenzamide-based tool compound PLK1 inhibitor in enzyme activity...
Items per page:
1 - 10 of 134